Antibody News and Research

RSS

An antibody is a blood protein that is produced in response to and counteracts an antigen. Antibodies are produced in response to disease and help the body fight against the particular disease. In this way, antibodies help the body develop an immunity to disease.

B.1.617.2 variant of SARS-CoV-2 is partially resistant to antibody-mediated neutralization

A team of scientists from France has recently conducted a study to evaluate the sensitivity of the B.1.617 variant of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) to antibody-mediated neutralization.

31 May 2021

Synbal and La Jolla Institute for Immunology collaborate to develop better COVID-19 models

The La Jolla Institute for Immunology (LJI) is partnering with Synbal, Inc., a preclinical biotechnology company based in San Diego, CA, to develop multi-gene, humanized mouse models for COVID-19 research. The research at LJI will be led by Professor Sujan Shresta, Ph.D., a member of the Institute's Center for Infectious Disease and Vaccine Research.

29 May 2021

New LNP-based mRNA vaccine candidate protects against lethal SARS-CoV-2 in preclinical trials

A new study, published in Nano Letters, describes an effective new COVID-19 vaccine candidate based on a messenger ribonucleic acid (mRNA) platform.

28 May 2021

Glycosylation a significant element in SARS-CoV-2 infection and vaccine design, says study

A new study by researchers from Taiwan and the US suggests that the removal of unnecessary glycans from spike glycoprotein of the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) exposes highly conserved sequences and opens the door for the development of broadly protective vaccines against the virus and its variants.

28 May 2021

Study supports single-dose COVID-19 vaccine strategy for previously infected individuals

Researchers in the Netherlands have provided evidence that a single dose of Pfizer-BioNTech’s coronavirus disease 2019 (COVID-19) vaccine is sufficient to protect against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) among people who have already been infected with the virus.

28 May 2021

Identifying SARS-CoV-2 epitopes targeted by current vaccination could help improve future vaccines

Researchers in the United States have identified antibody-inducing epitopes of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) in individuals vaccinated against coronavirus disease 2019 (COVID-19) that could be used for future diagnostics, therapeutics, and vaccine design.

28 May 2021

Will emerging SARS-CoV-2 variants affect T cell immunity? A meta-analysis

New research by a team of scientists at The Hong Kong University of Science and Technology sheds light on the epitopic targets of SARS-CoV-2 by T cells in COVID-19 convalescents. The team’s findings suggest that the epitopes targeted by T cells during infection may not be affected by the emergence of SARS-CoV-2 variants.

28 May 2021

Aptamer Group collaborates with world-leading pharmaceutical company to evaluate Optimer technology

Aptamer Group today announced that it has signed an agreement with the multinational pharmaceutical and biopharmaceutical company Takeda.

From Aptamer Group 28 May 2021

Researchers discover cross-reactive coronavirus antibody triggered during COVID-19 infection

Even before the COVID-19 pandemic, most people in the United States already had been sick with a coronavirus, albeit a far less dangerous one.

28 May 2021

Is a single Pfizer/BioNTech COVID-19 vaccine dose sufficient for individuals with prior SARS-CoV-2 infections?

A team of scientists from Spain has recently evaluated the immune responses induced by mRNA-based Pfizer/BioNTech coronavirus disease 2019 (COVID-19) vaccine in healthcare workers with or without a history of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection.

27 May 2021

Higher CD8 T cells may influence COVID-19 recovery in blood cancer patients

Antibodies aren't the only immune cells needed to fight off COVID-19 - T cells are equally important and can step up to do the job when antibodies are depleted, suggests a new Penn Medicine study of blood cancer patients with COVID-19 published in Nature Medicine.

27 May 2021

Pfizer-BioNTech COVID-19 vaccine may not be associated with adverse effects on fertility and breastfeeding, says study

A recent study by researchers in Singapore shows the absence of evidence for adverse effects on fertility or the presence of the vaccine mRNA (messenger ribonucleic acid) in breast milk, following the administration of the Pfizer BNT162B2 COVID-19 vaccine. This supports efforts to prevent the spread of false information about the effects of the vaccine.

27 May 2021

Nanobody inhalation found to be effective against COVID-19 in hamsters

In a recent paper, researchers describe an aerosolized nanobody formulation that was found to effectively block SARS-CoV-2 in Syrian hamsters.

27 May 2021

Rapid Novor First to Decode Polyclonal Antibodies Using Only Proteomics

Novel antibody discovery platform REpAb® unlocks direct access to key antibodies through next-generation protein sequencing

From Rapid Novor Inc 27 May 2021

Waters Introduces the SARS-CoV-2 LC-MS Kit (RUO) to Advance Clinical Research of Infectious Diseases

Waters Corporation today introduced a new RUO LC-MS test method to advance critical infectious disease research.

From Waters Corporation 27 May 2021

New DNA COVID-19 vaccine proven effective in mice

A new study has shown that a new DNA-based COVID-19 vaccine successfully induced immunization against SARS-CoV-2 in mice and hamsters.

27 May 2021

Study shows CoronaVac to have high seroconversion rate after 40 days

Researchers from the Federal University of Paraná, Brazil, looked into the seroconversion rate after vaccination with the CoronaVac. Using immunoassays, they measured the immunoglobulins (IgG) for anti-nucleocapsid protein (anti-N) antibodies and anti-spike-1 (anti-S1) protein antibodies.

27 May 2021

Disproportionate number of SARS-CoV-2 breakthrough infections are caused by variants of concern

A study conducted by researchers in the United States has shown that among twenty patients with breakthrough infection following vaccination against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) – the agent that causes coronavirus disease 2019 (COVID-19) – all of the infections were caused by variants of concerns.

26 May 2021

Reducing COVID-19 burden with monoclonal antibodies and vaccination

Researchers in the United States, the UK and France have shown that using antiviral monoclonal antibodies in combination with vaccination can be expected to suppress the transmission of severe acute respiratory syndrome coronavirus 2 (SARS CoV-2) and reduce the burden of coronavirus disease 2019 (COVID-19) more than vaccination alone.

26 May 2021

Researchers identify structure of agent that causes Alzheimer's and Parkinson's diseases

Alzheimer's disease - also called dementia - where memory and cognitive functions gradually decline due to deformation and death of neurons, and Parkinson's disease that causes tremors in hands and arms impeding normal movement are major neurodegenerative diseases.

26 May 2021

Antibody News and Research

Further Reading

B.1.617.2 variant of SARS-CoV-2 is partially resistant to antibody-mediated neutralization

Synbal and La Jolla Institute for Immunology collaborate to develop better COVID-19 models

New LNP-based mRNA vaccine candidate protects against lethal SARS-CoV-2 in preclinical trials

Glycosylation a significant element in SARS-CoV-2 infection and vaccine design, says study

Study supports single-dose COVID-19 vaccine strategy for previously infected individuals

Identifying SARS-CoV-2 epitopes targeted by current vaccination could help improve future vaccines

Will emerging SARS-CoV-2 variants affect T cell immunity? A meta-analysis

Aptamer Group collaborates with world-leading pharmaceutical company to evaluate Optimer technology

Researchers discover cross-reactive coronavirus antibody triggered during COVID-19 infection

Is a single Pfizer/BioNTech COVID-19 vaccine dose sufficient for individuals with prior SARS-CoV-2 infections?

Higher CD8 T cells may influence COVID-19 recovery in blood cancer patients

Pfizer-BioNTech COVID-19 vaccine may not be associated with adverse effects on fertility and breastfeeding, says study

Nanobody inhalation found to be effective against COVID-19 in hamsters

Rapid Novor First to Decode Polyclonal Antibodies Using Only Proteomics

Waters Introduces the SARS-CoV-2 LC-MS Kit (RUO) to Advance Clinical Research of Infectious Diseases

New DNA COVID-19 vaccine proven effective in mice

Study shows CoronaVac to have high seroconversion rate after 40 days

Disproportionate number of SARS-CoV-2 breakthrough infections are caused by variants of concern

Reducing COVID-19 burden with monoclonal antibodies and vaccination

Researchers identify structure of agent that causes Alzheimer's and Parkinson's diseases

Using single B cell screening to boost antibody discovery eBook

Latest eBooks

Industry Focus eBook - Analytical Chemistry (3rd edition)

Industry Focus eBook - Microbiome (1st edition)

Industry Focus eBook - Cell biology (5th edition)

Advancing degrader and proximity-based drug development

Designing fluidic architecture for scalable diagnostic platforms

Evaluating new approaches for rare disease genomics

Expanding access to NMR with the Fourier 80 Duo